ITP - Immune Thrombocytopenia
Conditions
Brief summary
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
Interventions
DRUGEltrombopag
ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
Sponsors
Sohag University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver
Exclusion criteria
Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| •To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag. | 3-6 months after receiving eltombopag | the incidence and severity of liver dysfunction in ITP patients |
Countries
Egypt
Contacts
Primary ContactPeter A Alfy, Resident
Backup ContactUsama M Abdelaal, Professor
Outcome results
None listed